POPULARITY
5 episodes with Leo Pharma
2 episodes with Leo Pharma
2 episodes with Leo Pharma
2 episodes with Leo Pharma
4 episodes with Leo Pharma
6 episodes with Leo Pharma
4 episodes with Leo Pharma
3 episodes with Leo Pharma
2 episodes with Leo Pharma
⚠️ Warning: Listening to this episode may cause spontaneous inspiration, side effects include rethinking innovation, falling in love with Denmark, and Googling “intelligent bricks.” Meet Anne C. Fleischer — engineer, innovator, former LEO Pharma exec, and now leading Consumer Engagement & New Business Models for Obesity at Novo Nordisk. She grew up in a village so small that your soccer team was whoever showed up to class that day. She wanted to be a helicopter pilot or a doctor, but got motion sickness and couldn't get into med school...... So she built a new path- literally - constructing heart pump mannequins, NFC-enabled pavement tiles, and eventually digital health products that helped millions.
CDMO Live 2025 Highlights: How Bayer, Boehringer Ingelheim, and Leo Pharma are rebuilding manufacturing strategiesComplexity Challenge: With thousands of SKUs to manage (Bayer handles 5,000+, half outsourced), companies struggle with aging portfolios and aggressive commercial expansion.Geopolitical Reshuffling: A staggering 62% of pharma companies are restructuring their manufacturing footprints in response to global tensions.Different Resilience Approaches:- Boehringer Ingelheim (family-owned) maintains dual sourcing despite higher costs- Leo Pharma focuses on strategic partnerships for smaller-volume products- Bayer's "Project Martini" shifts from Euro-centric to regional productionAI Adoption: Still early days, but promising applications in contract management, document processing, and predictive maintenance are emerging.Sustainability Shift: While not top priority, sustainability is increasingly viewed as both an ethical necessity and long-term cost reducer.Bottom Line: The industry is moving from pure cost optimization to balancing affordability with resilience. As Blue Jet Healthcare's MD put it: "resilience is becoming as important as costs."Download the full report
Denne gang sætter ‘Ramt af livet' fokus på kronisk håndeksem – en invaliderende hudsygdom, der rammer hænderne og viser sig som tør, revnet og kløende hud. En sygdom, der kan få store konsekvenser for både arbejdsliv og selvværd.For 35-årige Natasha har det betydet et farvel til drømmejobbet som frisør, fordi hun ikke længere kunne arbejde med vand, kemikalier og handsker. I podcasten deler hun sin personlige historie – om sorgen ved at måtte skifte fag og om kampen for at finde ro i en krop, der konstant klør.Podcasten er produceret af SundhedsTV og udgives i samarbejde med Helse. Afsnittet er sponsoreret af Leo Pharma.
We're in Copenhagen
Did you know that many conditions treated by Big Pharma can be inexpensively corrected with vitamin D?Leo Pharma and Almirall are two pharmaceutical companies that specialize in dermatology. Many of their products contain synthetic vitamin D for skin problems. Coincidentally, these companies also played a role in the sun-phobia movement. The sun is one of the best remedies for skin problems like eczema and psoriasis. You need at least 10,000 IUs of vitamin d3 every day to maintain healthy vitamin D levels!Sunbathing was once popular worldwide and was used to prevent tuberculosis and various health conditions. However, after the development of antibiotics, its popularity drastically declined.Dr. William Grant has done extensive research on vitamin D. He explains that 84,532 papers have been published on vitamin D, the most studied bioactive molecule. Despite the evidence, there is still controversy regarding the health benefits of vitamin D. Tens of thousands of research studies have been conducted on the benefits of vitamin D for cancer. Big Pharma has influenced studies that discredit the benefits of vitamin D. Only small amounts of vitamin D were used in most studies that do not show favorable outcomes with vitamin D. Dr. Cicero Coimbra, who developed the Coimbra protocol, has seen a 90% success rate in using vitamin D for autoimmune diseases. Some people have vitamin D resistance, which involves a genetic problem with vitamin D. Blood tests can not accurately determine vitamin D deficiency. It is vital to keep your vitamin D levels over 50 ng/mL to avoid vitamin D deficiency. Dr. Eric Berg DC Bio:Dr. Berg, age 59, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.
In this episode of our CVC series, Andreas Munk Holm and our CVC in-house expert, Jeppe Høier, talk with Gitte Aabo to explore the world of corporate venture. With a remarkable background that spans 27 years at Leo Pharma, including 12 years as CEO and further experience at GN Hearing, Gitte shares her journey in building innovation initiatives like Leo iLab. She explains how she helped develop digital tools to improve treatment outcomes and diagnostics, drawing on her extensive experience in both board leadership and hands-on management to drive change.During the conversation, Gitte dives into aligning corporate culture with innovative practices. She emphasizes that success in corporate venturing doesn't come from following a one-size-fits-all formula but from ongoing, one-on-one discussions with board members and key executives. By integrating strategic insights with practical initiatives, she shares how innovation teams must work closely with the core business to ensure long-term impact, even if the financial returns take time to materialize.Chapters:03:55 Establishing Leo Innovation Lab04:15 Digital Tools for Skin Disease Treatment05:01 Improving Diagnosis with Mobile Tools05:16 Philosophy of Patient Focus06:20 Structure and Funding of Leo iLab08:10 Challenges and Learnings from Leo iLab08:28 Collaboration with US and External Investments09:31 Balancing Innovation and Core Business11:24 Reflections on Corporate Innovation14:43 Transition to GN Hearing15:50 Integrating Innovation in GN Hearing17:00 Strategic Partnerships and External Innovation19:52 Challenges in Corporate and Startup Collaboration
Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353 – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027
The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly laid down up to $2.5 billion for Scorpion's PI3Kα inhibitor program. Meanwhile, the immunology and inflammation space continues to fire on all cylinders as Gilead invests up to $1.7 billion for LEO Pharma's preclinical oral small molecule STAT6 program. And those are only the deals accepted by both parties. Prior to the conference, Biogen offered to acquire its struggling neuro partner Sage Therapeutics for around $469M. The proposal follows a catastrophic run for Sage, which has seen its shares fall more than 90% in the past two years. 2024 sales and earnings forecasts have also generated attention this week, with Sarepta reporting that Duchenne muscular dystrophy gene therapy Elevidys beat analysts' expectations in the fourth quarter, and Eli Lilly projecting a full-year revenue miss driven largely by lower-than-expected sales of GLP-1 blockbusters Zepbound and Mounjaro. As expected, obesity has been a hot topic at JPM, with Pfizer CEO Albert Bourla announcing that his company is going “all in” in the space. This follows new FDA guidance revealed last week recommending a minimum weight loss threshold for drug developers. Among the many companies taking notice is newcomer Verdiva Bio, which launched last week with more than $410 million in opening funds. Also debuting last week was Kardigan, which raised $300 million to tackle heart disease. Kadigan joins a resurgent cardiovascular space, where several companies—including those developing gene therapies—are targeting myriad diseases. Finally, BioSpace senior editor Annalee Armstrong caught up with Daphne Zohar, CEO of BioSpace NextGen 2025 company Seaport Therapeutics Daphne Zohar, who offered her thoughts on the current state of the neuropsychiatric space.
In this episode, Dr. Kenneth Lyons Jones, one of the pioneers who first identified Fetal Alcohol Spectrum Disorders (FASD) in the United States in 1973, and Dr. Christina Chambers, a renowned epidemiologist who has conducted groundbreaking research on the prevalence of FASD, join host Chris Stallman, CGC, to discuss the discovery of FASD, its common physical and cognitive traits, and its prevalence today. BONUS: Earn continuing education credits for listening to our entire FASD 3-part series. Scroll down to learn more. Resources Mentioned in This Episode: Dr. Kenneth Lyons Jones on the History of Fetal Alcohol Syndrome - FASD Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities | Antenatal Exposures and Child Outcomes | JAMA | JAMA Network Fetal Alcohol Spectrum Disorders – American Academy of Pediatrics Types of Treatment for FASDs | Fetal Alcohol Spectrum Disorders | CDC Choline supplements in young children with fetal alcohol spectrum disorder have lasting cognitive benefits | National Institute on Alcohol Abuse and Alcoholism (NIAAA) _______________________________________________________________________________________________________ MotherToBaby: FASD Podcast SCPD4929 PROGRAM DESCRIPTION: This podcast series is intended to reach various audiences, including healthcare professionals, who can use the information presented to inform their practice and their interaction with clients/patients. The podcast episodes will educate participants on 1) the discovery, prevalence, and newest research on the topic of fetal alcohol spectrum disorders (FASDs), 2) CDC's work in addressing prenatal alcohol and other substance use and FASDs, and 3) the experiences of people living with FASDs. OBJECTIVES: After completing this course, the learner will be able to: 1. Describe Fetal Alcohol Spectrum Disorders (FASDs). 2. Describe the National Center of Birth Defects and Developmental Disabilities' (NCBDDD) approach to addressing FASDs. 3. Describe the impact on people who are living with FASDs. 4. Describe how interprofessional collaboration addresses FASDs. 5. Describe how interprofessional teams can help people living with FASDs transition from pediatric to adult healthcare. FACULTY/ CREDENTIALS: Laura Bousquet, Family Navigator/Self-Advocate, FASD United Christina Chambers, PhD, MPH, Distinguished Professor of Pediatrics, University of California, San Diego Elizabeth Dang, MPH, Behavioral Scientist, Centers for Disease Control and Prevention Nicholas Deputy, PhD, MPH, Health Scientist, Centers for Disease Control and Prevention Kenneth Jones, MD, Distinguished Professor of Pediatrics, University of California, San Diego Chris Stallman, MLS, MS, CGC, Director, MotherToBaby Arizona, University of Arizona Jennifer Wisdahl, Chief Operating Officer, FASD United CE ORIGINATION DATE: CE EXPIRATION DATE: January 9, 2025 January 9, 2027 URL https://momtobaby.org/FASDep81youtube INTENDED AUDIENCE: Advanced Practice Nurses, Certified Health Educators, Medical Assistants, Licensed Practical/Vocational Nurses, Physicians, Physician Assistants, Registered Nurses, and Social Workers PREREQUISITES: Learners will have a basic understanding of what fetal alcohol spectrum disorders are. FORMAT: This activity is Web on Demand CONTACT INFORMATION: CDC's CE Accreditation Team has a policy for grievances that is available upon request. Division of Birth Defects and Infant Disorders cdcinfo@cdc.gov ACCREDITATION STATEMENTS: In support of improving patient care, this activity has been planned and implemented by the Centers for Disease Control and Prevention and MotherToBaby. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CNE: The Centers for Disease Control and Prevention designates this activity for 0.5 nursing contact hours. CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program. CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 0.5. CDC provider number 98614. DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use. CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Christina Chambers, PhD, MPH and she wishes to disclose she receives research funding from Amgen, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer, Inc., Regeneron, Hoffman La-Roche-Genentech, Genzyme Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Sanofi, UCB Pharma, USA, Leo Pharma, Sun Pharma Global FZE, Gilead, Novartis, and the Gerber Foundation. All relevant financial relationships listed for this individual have been mitigated. Content will not include any discussion of the unlabeled use of a product or a product under investigational use. CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity. The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex (including pregnancy, sexual orientation, and gender identity). To learn more visit: https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html. Instructions for Obtaining Continuing Education (CE) To receive continuing education (CE) for SCPD4929 – MotherToBaby: FASD Podcast, please visit CDC TRAIN and search for the course in the Course Catalog using SCPD4929 Follow the steps below by January 9, 2027. Register for and complete the course. Pass the post-assessment at 75 %. Complete the evaluation. Visit Your Learning to access your certificates and transcript. FEES: No fees are charged for CDC's CE activities. ______________________________________________________________________ Looking for even more education about FASD? Don't miss a special free Birth Defects Awareness Month webinar January 31, 2025 at 9a PT/12p ET. The webinar will be presented by Dr. Noemi Spinazzi of the American Academy of Pediatrics. It is a free webinar, but advanced registration is required at the following link: https://momtobaby.org/FASDwebinar2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 December 2024. In this episode: Zepbound bests Wegovy; Novartis and PTC's Huntingdon's deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic's hopes for MS drug. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-FU2EL35AAJBGLIK4EL7KVQRAGU/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
(+luftalarm i Ukraine og Leo Pharma på børsen) Det er tid til at gøre status. Alle C25-virksomheder har endelig aflagt regnskab for efteråret. Hvem ligger i bunden? Og hvem er helt i top? Og hvad er status egentlig på dansk erhvervsliv lige nu? Vi skal også med nattog til Ukraine. En erhvervsdelegation har været afsted. Men hvordan og hvorfor driver Carlsberg bryggeri, og hvordan sælger Jysk madrasser i et land i krig? Og så vender vi Leo Pharmas udmelding om, at de vil på børsen i 2026. Vært: Ulrik Rosenkvist Schultz. Fast gæst: Sune Aagaard. Medvirkende: Per Hansen, investeringsøkonom hos Nordnet og Casper Schrøder, DR's økonomikorrespondent.
Leo's Brian Hilberdink, EVP and president, talks with Jack O'Brien about how the drugmaker is seeding the market ahead of the anticipated launch of its topical eczema treatment.And for our Trends segment, we'll take a look back at highlights from last Wednesday's MM+M Media Summit in NYC.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Host Fred Goldstein invites Brian Hilberdink, President, Executive Vice President North America and Douglas Maslin, MD, Global Principal Medical Advisor to discuss LEO Pharma and their involvement with AMCP. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
This podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics: Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation Expert guidance for accurate diagnosis and work-up of CHE patients Challenges and limitations of current therapeutic offerings The potential of a topical novel pan-JAK inhibitor for targeted treatment of CHE
Today, we're excited to welcome Brian Hilberdink, Executive Vice President of North America and President of Leo Pharma, Inc. With over 26 years of experience at Novo Nordisk, Brian's journey from managing theme parks to shaping the future of medical dermatology is truly inspiring. In this episode, Brian shares the critical role of fostering cross-organizational alignment and the importance of transitioning from traditional R&D to "Search and Development" to address unmet needs in medical dermatology. He also discusses Leo Pharma's strategy of "putting pearls on a string" to build a portfolio of value-driven assets and his experience in navigating cultural differences when working with global teams. Get ready for a captivating conversation filled with practical advice and leadership insights!
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L'Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400085- 1.0 - 08/2024 MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026
“Building mutual understanding and trust is the foundation for optimising performance and driving innovation with contract manufacturing organisations (CMOs),” says Guosheng Zhao, Senior External Manufacturing Lead at LEO Pharma. Guosheng Zhao brings years of experience in procurement, management consulting at PWC, and working with contract manufacturers at companies such as Procter and Gamble and Philips to his role. At LEO Pharma, Guosheng is responsible for external manufacturing of dermatology and thrombosis medicines, a portfolio spanning both small molecules and biologics, with a focus on maintaining stable product supply and quality across complex global supply chains. In the latest PharmaSource podcast episode, Guosheng explains why effective supplier relationship management is crucial for reducing costs, improving margins, and ensuring consistent medicine supply for patients. Read the full article on PharmaSource
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026
Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024 MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026
Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026
Digital transformation er som fitness - det stopper aldrig. Dagens gæster kommer fra en over 100 år gammel medicinalvirksomhed, hvor innovation er selve eksistensgrundlaget, når de produkter, der skal bære forretningen om 10 år, bliver udviklet. Så hvordan ser digital transformation ud i en organisation, der altid skal være foran? Lyt med i Dataklubben, der besøger LEO Pharma til en snak om at lede den digitale transformation, nytænke rammerne og sikre datastrategien i en særledes kompetent organisation. Tag godt imod dagens gæster fra Global IT i LEO Pharma - Troels Ravn Bærentzen, Head of Digital Strategy, Partnerships & Analytics og Marie Helene Andersson, Corporate Principal Data Partner.
SD231 - Inteligência Artificial para apoio em diagnósticos. Neste podcast, Dr. Lorenzo Tomé conversa com o cofundador e CEO da PickCells, Paulo Melo, para falar sobre o uso da inteligência artificial para diagnósticos, algorimos, dados e a atuação das big techs. A PickCells é uma startup que oferece ferramenta com uso de IA para suporte ao diagnóstico, patologia digital e melhoraria da experiência dos profissionais que trabalham com rotina de análises de amostras. Participe das nossas comunidades médicas! Para web, acesse AQUI. Baixe nosso app: Android ou IOS Neste episódio, o que você vai encontrar: O Background do Paulo Ele é administrador de formação com MBA em Gestão Executiva Internacional, trabalhou em grandes farmacêuticas como Roche e LEO Pharma. Atuou como consultor para uma empresa chinesa entre outras atividades até começar a empreender. Ele atualmente está concluindo seu Mestrado em Administração com foco em Gestão do Desenvolvimento Local Sustentável. Comunidade Online Saúde Digital Podcast Você é médico? Quer interagir com o Lorenzo Tomé e com outros colegas inovadores da medicina digital? Entre na Comunidade do Podcast Saúde Digital na SD Conecta! Assista este episódio também em vídeo no YouTube no nosso canal Saúde Digital Ecossistema! ACESSE AQUI! Episódios Anteriores - Acesse! SD230 - Internacionalização de empresas para o Reino Unido SD229 - Fomento de negócios para startups SD228 - Healthtech de saúde do Brasil para o mundo Músicas: | Declan DP – We Are Here | Declan DP – Raindrop | Declan DP - Island "Music © Copyright Declan DP 2018 - Present. https://license.declandp.info | License ID: DDP1590
In many respects, bringing an established foreign biopharma company to the U.S. market is not unlike starting one up from scratch. In other respects, it's even harder; long-held cultural norms and management styles, region-specific market dynamics, payer system nuance, and political influence must all be re-navigated and re-negotiated without encumbrance. The job's not for the faint of heart, which might be why the Danish company LEO Pharma tapped veteran biopharma leader Brian Hilberdink to lead its U.S. operations. On this episode of the Business of Biotech, Hilberdink shares loads of biopharma-specific leadership intel and advice as we discuss the task he faces and the course he's charting. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Discover shared and unique features of type 2 inflammatory diseases and how multi-disciplinary care can benefit patients. Join Profs. Klaus Rabe and Stephan Weidinger as they explore how chronic underlying type 2 inflammation manifests in different organs to drive pathology in atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis; and discuss how these commonalities translate into shared decision-making and multidisciplinary care in clinical practice. ADVENT is a medical education non-promotional for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Klaus Rabe, MD, PhD: Grants and research support: German Federal Ministry for Research and Technology (BMFT); Honoraria or consultation fees: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, Regeneron, Verona Pharma; Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL) Stephan Weidinger, MD, PhD: Speaker, advisory board member, and or investigator for: AbbVie, Almirall, Galderma, Kymab, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302410 v2.0 07/2023 MAT-US-2304930 v1.0-P Exp. Date 07/07/2025
Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting. This episode offers guideline insights into the applications recently approved therapies that have been approved by the FDA and/or the EMA, including cabozantinib, selpercatinib, pralsetinib, and entrectinib. It also provides data updates of previously approved therapies and how guidelines have been adapted accordingly. To answer questions on the 2022 ESMO Clinical Practice Guideline update, we have invited Dr. Ahmad Awada to join us. He is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium. Target Audience: Oncologists, pathologists and other HCPs involved in the management of advanced thyroid cancer, with a focus on community practitioners. Learning objectives: After completing this educational activity, learners will be able to: Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines, and identify ways to adapt the guidelines to local settings Discuss precision medicine and new technologies, including liquid biopsy Review the organization of care and strategies for more efficient care delivery Funding information: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity. Disclosures Dr. Ahmad Awada declares the following financial relationships from the past 24 months: Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genomic Health, Ipsen, Leo Pharma, Eli Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: N/A
Today we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation.Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a higher degree of efficacy. When it comes to bringing a drug through the entire clinical value chain, there is a lot of uncertainty as it is. When you are trying to aim for innovation, the uncertainty increases. What this uncertainty does to a company depends on the company size. Being in a mid-sized pharmaceutical company means that there is some room for taking risks, but also a need to balance the uncertainty with the need to ensure continued operations. We dive into what this means for trial design in different stages of clinical trials - and how some of these stages can be outsourced, whereas others should be best kept in house to build relationships with HCPs pre-drug launch. We speak about leadership in the clinical area - and the benefits of understanding the entire clinical life cycle. Drug development is both an innovation game and a horse race. Leadership is what will allow your organization to run fast - but also dare to fail in pursuit of a deep purpose. Lars recently re-organized his leadership team to structurally ensure cross-functional collaboration and drive a competitive edge. We speak about the ideas behind this restructuring, and also how it has addressed some of the most stubborn challenges of our industry. Off-mic, Lars Rosendal and Ivanna Rosendal did try to figure out if there is a family relation - but there did not appear to be one. Guest:Lars Rosendalhttps://www.linkedin.com/in/lars-rosendal-2520a16/ LRXDK@leo-pharma.com ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page
En este episodio entrevistamos a la biotecnóloga Ester Caffarel, quien fue directora asociada de LEO Pharma y actualmente es directora asociada de Chiesi. Ester nos hará un recorrido por su trayectoria profesional y nos hablará sobre su transición fuera de la academia y su experiencia en el ámbito de la consultoría. También nos hablará sobre la conciliación en Estados Unidos y la importancia del networking, entre otros.
In this week's episode, Helena is joined by Paul Simms, CEO of Impatient Health, to delve deeper into GOLD's recent cover feature on reframing pharma's bad boy reputation. They chat about the current state of pharma's reputation and the influence of the media and pop culture on this, the ways in which pharma can recover and bolster its reputation, and more. And in ‘news you might have missed', Helena discusses the latest global awareness campaign from Leo Pharma, the ABPI's recent survey on pharma and academia collaboration and a new Marvel comic strip features Pfizer's COVID-19 vaccination efforts in the US. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation Talking to Paul Simms https://www.emg-gold.com/post/podcast-talking-to-paul-simms
Christopher Posner Chief Executive Officer, President, and Director Mr. Posner has served as our President and Chief Executive Officer since November 2021 and has served as a member of our Board since August 2018. He has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. From July 2017 to October 2021, he served as the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University. Please see korsuva.com/pi for Full Prescribing Information.
This podcast is only for use by healthcare professionals. This educational podcast has been fully sponsored by UCB and the content does not necessarily reflect the views of UCB. Speaker Disclosure: Prof. Paulo Gisondi has participated to boards and acted as a speaker for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Eli-Lilly, Janssen, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, UCB Pharma. Privacy Policy: For further information on how UCB processes personal data, visit: https://www.ucb.com/Privacy-policy-for-Healthcare-Professionals This EMG-Health podcast explores options for treating females with psoriasis and questions the surrounding factors that must be taken into consideration. Featuring the expert opinion of Paolo Gisondi, Associate Professor of Dermatology and Venereology, University Hospital of Verona, Italy, this podcast explores sex-specific challenges in patients with psoriasis with articular manifestations.
In this episode, Helena is joined by Klaus Legau, Senior Advisor, Social Sustainability at Leo Pharma. Klaus reveals the most important facets of a social sustainability strategy and where he believes the pharmaceutical industry is falling short in this respect, as well as offering expert advice to those starting out in policy campaigning. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change Novartis enhances social mobility commitments https://www.emg-gold.com/post/novartis-enhances-social-mobility-commitments A joint mission for social justice https://www.emg-gold.com/post/a-joint-mission-for-social-justice Setting the stage for a more equitable future https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
Medsider Radio: Learn from Medical Device and Medtech Thought Leaders
In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world's most successful medtech founders and executives. If you're interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Robert if you'd rather read it instead.
Dr. Mads Krogsgaard Thomsen, DVM, DSc., Ph.D., is the CEO of the Novo Nordisk Foundation (https://novonordiskfonden.dk/), an international foundation with a dual objective: to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group (of which Novo Nordisk A/S is the largest holdings) and to support scientific, humanitarian and social purposes. In 2020, the Novo Nordisk Foundation had a net worth of US$73.1 billion, making it the largest financial endowment in the world. Novo Nordisk Foundation owns Novo Holdings A/S, a holding company and majority shareholder of Novo Nordisk, as well as Novozymes, a global biotechnology company focused on the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The foundation is also a major shareholder in more than 75 other companies. Originally, trained as a veterinarian / DVM at The Royal Veterinary and Agricultural University (now part of the University of Copenhagen), where he also holds a DSc. in this domain, Dr. Thomsen started his career as a PhD pharmacology student at the University of Copenhagen, after which he worked three years as a researcher at LEO Pharma. Thirty years ago, he joined Novo Nordisk, initially as Head of Growth Hormone Research and subsequently as Senior Vice President of Diabetes R&D. In 1995, he was appointed Senior Vice President of Discovery and in 2000, he became Executive Vice President of Research & Development/Chief Scientific Officer. Over the years, he has headed the development of 20 medical drugs, especially within diabetes treatment and the groundbreaking development of GLP-1 technologies. Dr. Thomsen has served as President of the Danish Academy of Technical Sciences and Chairman of the Board of the University of Copenhagen, where he is also an adjunct professor of Pharmacology.
Sven Schimansky-Wabra ist seit 2004 in der Pharma-Welt tätig, begonnen bei Schering über Intendis Dermatologie bis hin zu Bayer. 2012 hat er aus eigenem Antrieb Bayer verlassen und die Skin Care Pharma aufgebaut. Die Skin Care hat die generische Version „Skinatan“ zu Advantan entwickeln lassen und erfolgreich durch die Zulassungsstudien gebracht. Advantan erwirtschaftete 2018 einen Umsatz von ca.: 80 Mio. € weltweit und ist in der Indikation Neurodermitis zugelassen. Inhaber des Originals ist Leo Pharma. Aktuell bestehen Lizenzverträge in 7 EU-Ländern, in denen die Skin Care auch selbst die Zulassungsverfahren betreibt. Des Weiteren ist Sven Schimansky-Wabra auch in der DEGODE engagiert und hat dort die generische Version „Beloren“ zu Skinoren entwickeln lassen. Es bestehen Lizenzverträge in 11 EU-Ländern, in denen die DEGODE noch 2019 selbst die Zulassungsverfahren betreiben wird. 2018 erwirtschaftete das Original Skinoren in über 60 Ländern einen Umsatz von über 130 Mio. € und ist in den Indikationen Akne & Rosazea zugelassen.
Anden episode byder på interview med CEO for Leo Innovation Lab, Anne Cathrine Fleischer. Leo Innovation Lab er en selvstændig virksomhed, udsprunget fra Leo Pharma. Til daglig beskæftiger virksomheden sig med hudsygdomme, og benytter en masse teknologier for bl.a. at skalere muligheden for behandling - for hvem har ikke ventet, hvad der føles som tre år på at komme til hudlægen? Hør for eksempelvis mere om hvilke teknologier der bliver brugt, hvordan de bliver brugt og hvordan de skaber værdi for forretningen. Du kan også høre om hvorfor virksomheden ligger selvstændigt fra Leo Pharma og hvad det betyder for arbejdet med innovation, data- og compliance overvejelser og meget mere. Vært: Mathias Møller Laugesen
Hvordan udviser man tillid, når man også har brug for en høj grad af kontrol? Hør Tanya Regnersgaard, Senior Director, Global Launch Management ved LEO Pharma, fortælle om den svære balance, og hvornår hun må give køb på kontrollen for til gengæld at se sine medarbejdere vokse i det tillidsrum, hun åbner for sine medarbejdere.
My guest today is Josh Corriveau, the Global Medical Affairs Director at Leo Pharma. We discuss the potential to make a career transition from MSL to Medical Director. In this episode we discuss: The transition from field medical to a medical director How Josh got the job and the responsibilities as a medical director What skills are mandatory to be considered for these types of roles Many Medical Director roles require an MD, would he say it makes it a lot harder if you are a Ph.D. or PharmD? His greatest challenges when transitioning into the Medical Director role Are all Medical Director roles in-house or can some of these roles be field-based? His advice to those in field medical transitioning out of COVID to field visit or hybrid of face to face and virtual interactions
My guest today is Abi Adenola, Medical Science Liaison at Leo Pharma. We discuss how to be a leader and mentor in your space and the importance of mentorship. In this episode we discuss: Abi’s background What made her want to transition to industry and how did she go about it “See one, teach one, be one” Can this concept be applied to any industry and if so, how? How important are mentors in the MSL role? Abi’s advice for MSLs and aspiring MSLs on how they can position themselves
Key takeaways:Learn how to lead a company through a CUSTOMER-DRIVEN purposeFind out the UNIQUE strategy GN Hearing deployed to survive and thrive in the pandemicThe value of being PEOPLE-CENTREDWhy Gitte's favourite day is MONDAY About Gitte:Gitte is President & CEO of GN Hearing and a member of the executive management since 2019. She brings a unique set of capabilities and values to the Executive Management within international management, finance, IT, sales, and marketing in the medical sector as well as deep insights into building digital communities. Gitte Aabo's career since 1992 has taken her through diverse managerial positions including finance, IT, and general management. In 2001, Gitte was appointed CFO and Senior Vice President, Finances & IT in LEO Pharma; in 2005, member of the Executive Board; in 2007, Deputy Group Managing Director, and from 2008 to 2019 Gitte Aabo was President and CEO in LEO Pharma. Gitte holds an MBA from Copenhagen Business School, an HD graduate diploma in business administration as well as a bachelor's degree in economy.Career inspiration, medtech opportunities, hiring solutions and market insights, all in one place. Find them here.
Dermatology News: Who’s at risk for depression on isotretinoin?: https://bit.ly/32AioXp Topical tapinarof effective in pivotal psoriasis trials: https://bit.ly/3pma0o0 Methotrexate users need tuberculosis tests in high-TB areas: https://bit.ly/3f0DcMV * * * Keeping up with the literature on atopic dermatitis (AD) is a challenge, with eight new articles posted on PubMed a day in 2020. Vincent A. DeLeo, MD, talks to Lawrence F. Eichenfield, MD, about quality of life in pediatric AD patients and how the condition affects parents/guardians, particularly in the form of sleep disturbances. Dr. Eichenfield also discusses studies that explore the impact of bathing frequency on the severity of AD as well as notable treatment advances in topical and systemic therapies in recent years. Reflecting on future research, Dr. Eichenfield posited if “recognizing significant disease early and instituting our more aggressive therapies early, will that change the development of comorbidities and will that burn out the disease more quickly or get sustained remission or cure as compared to just waiting?” Article: https://bit.ly/3f0DrHP Downloadable PDF: https://bit.ly/3lzuUy1 * * * Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles) Guest: Lawrence F. Eichenfield, MD (division of pediatric dermatology, departments of dermatology and pediatrics, University of California, San Diego, and Rady Children’s Hospital, San Diego) Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Eichenfield is an investigator for AbbVie, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. He also is a consultant for Almirall, Dermavant Sciences, Dermira, DS Biopharma, Eli Lilly, Forte Biopharma; Galderma Laboratories, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka Pharmaceutical, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme. Show notes by: Allegra Sparta, Melissa Sears * * * You can find more of our podcasts at http://www.mdedge.com/podcasts Email the show: podcasts@mdedge.com
In this episode of the podcast Gitte discusses telemedicine, GN Hearing's work in this area – and the impact of COVID-19, plus her time at LEO Pharma.
For 111 years, Danish multinational pharmaceutical company LEO Pharma has been innovating new products and solutions to help people achieve healthier skin. In 2019, LEO Pharma purchased Microsoft 365 with plans to deploy in companywide. When the COVID-19 pandemic created an urgent need they went all in, rolling out Teams from only 33 users to more than 6,000 users in the whole organization in just four days to help employees adapt and keep innovating through a crisis. Click here for transcript of this episode. Find out more about LEO Pharma on Twitter, Facebook, and LinkedIn. Watch the video: Microsoft Fireside Chat | LEO Pharma Microsoft Together Microsoft Teams Blog Microsoft 365 blog Microsoft Tech Community COVID-19 Business Resource Center Start your digital transformation now The Future of Work Explore tech for the modern workplace Listen and Subscribe to Modern Workplace at http://modernworkplace.mpsn.libsynpro.com/ Listen to other Microsoft podcasts at aka.ms/microsoft/podcasts
Dagens erhvervsoverblik: Den gamle og hæderkronede medicinalvirksomhed Leo Pharma overvejer børsnotering. Nordic Aviation Capital - ejet af Martin Møller - mister milliarder grundet corona. Pensionsplan kan give mindre banker stor ekstraregning. Og så langer Barack Obama hårdt ud efter Donald Trump. Vært: Lasse Ladefoged
Vil du beskrive dig selv som en leder med et stort drive, som altid er på udkig efter nye projekter? Eller kunne du godt tænke dig at prøve noget nyt? Tanya fortæller om sin rejse hos Leo Pharma, hvor hun er gået fra projektleder til leder af medarbejdere med globalt ansvar. Det betyder, at hun har haft et stort fokus på den rette målstyring på de projekter, hun har sat i søen. Det er man nødt til, når man opererer med globale teams – og på tværs af forskellige kulturer. ”Jeg kan godt lide at sætte noget i værk, hvor man kan se resultaterne”
Soulaima Gourani is a Young Global Leader of the World Economic Forum, and the owner of tradeconductor.com and womenreignite.com In this episode of ‘Mind, Money & Body’ Podcast, Gouraima shares her inspiring story as a global leader. Gouraima is a Danish Moroccan corporate advisor, speaker and writer based in Palo Alto, California. Key takeaways: Keep working towards your goals relentlessly. Keep learning and stay inspired. Learn from books, videos and various other resources. Adopt a helping attitude and support others too, in achieving their goals. Not everyone has access to resources and same level of privileges. Visit: https://womenreignite.com Read her book: https://bookboon.com/da/ignite-your-career-ebook Subscribe to the Podcast: http://marcom18.libsyn.com/success-against-all-odds She has authored several bestseller books on themes like “How to take control over your life” and “How to Design Your Future” and many others. She has worked with clients as Samsung, Roche A/S, Leo‐Pharma, NNIT, Genzyme, Aberdeen, DuPont, LEGO, McKinsey, DELL, Microsoft, Adecco, ManSoft, Alk Abello, Aon Hewitt, Citroen, Colliers, Diageo, Cisco, Ernst & Young, Volvo, FL Smidth, H. Lundbeck, IBM, TDC, SimCorp, Novo Nordisk, Novozymes, Danske Bank, News Corp and Deloitte etc. Her geographic experience includes 35+ countries: Denmark, Norway, Sweden, USA, Finland, Greenland, Austria, Hungary, Germany, UK, France, Italy, Saudi Arabia, Israel, Russia, Mongolia, Dubai, Sri Lanka, Myanmar, India, Greece, Thailand, Egypt, Venezuela, Morocco, Turkey, China, Lebanon, Japan, Switzerland, Mexico and Bahrain. She is a keynote speaker and an advisor to major companies on customer loyalty, strategic networking, change management, employee motivation and future of business. Subscribe the Podcast now to receive more such insightful content about financial, mental and physical well-being. Thank you. Vikram Jethwani Digital Strategist & Founder – Marcom18 www.marcom18.com --- Send in a voice message: https://anchor.fm/vikram-jethwani/message
MedWatch-redaktionen ser tilbage på ugen, der gik, hvor Leo Pharma og Lundbeck løb med noget af opmærksomheden. Elizabeth Mønsted Johansen, Albert Rønning-Andersson og Mikkel Aabenhus Hemmingsen er i studiet.
This was an incredible conversation that I was privileged to be part of as Aga and OI went deep into culture, leadership, courage, change, experimentation, personal agency, accountability and so much more. Some quotes from this brilliant conversation to pique your interest include: - "we are wired for choice and polarities" - "it is impossible to make a huge change and a major overhaul of these systems and world views. The only thing you can do is introduce a tiny change and see how that system reacts to that" - “What is the smallest possible change that I could make to maintain the biggest part of the algorithm, change a small part, but at the same time have a huge impact” - “I think that we have way more power in our hands than we want to believe” - “The people that I consider to be cultural revolutionaries, one of the characteristics is that they lead from the heart and purpose rather than the ego” - “Culture is not just global, culture is very much local” Aga can be found via the following means: Website - https://www.agabajer.com/ LinkedIn - https://www.linkedin.com/in/agabajer/ Bio: Aga works with leaders and teams around the globe to help them bring their vision to life. She is the co-author of “Building and Sustaining a Coaching Culture” - a complete guide on how to embed continuous learning in organisations' DNA. She is also the host of one of the most popular podcasts on culture, the CultureLab. The question at the core of her work is: “How can we harness the power of culture to create a world where people love showing up at work?” Aga blends experience as: • a leader, in companies big and small • an experienced consultant • an executive and team coach • a researcher and an author • a podcast host and a blogger • an entrepreneur with her unstoppable and insatiable curiosity about what works and what doesn’t work in organisational and social change. Her approach is science and evidence based. She makes the complex issue of culture, change and team dynamics as simple (but not simpler) as possible, uncovering all the crucial and fundamental forces at play, so that you can take the right actions to bring about the change you seek. Aga has worked with senior leadership of many major organisations, including the Hilton Hotels and Resorts, Citibank, Toyota, Porsche, GlaxoSmithKline, AstraZeneca, Leo Pharma, Hellenic Bank, Eurolife, Bank of Cyprus, Eurobank, Wargaming, Sanofi, Amdocs, SAP, MSX, Heineken, the European Patent Ofce and many, many others. Please find my Interpersonal Catalyst brochure here in case I can support you at all -> https://my.visme.co/projects/rxyz4jpo-garry-turner-interpersonal-catalyst --- Send in a voice message: https://anchor.fm/valuevulnerability/message
MedWatch-redaktionen taler om biotekselskabet Orphazyme, Sanofis exit fra diabetesmarkedet og Leo Pharmas nye studieresultater, der giver håb om at kunne konkurrere med blockbustermidlet Dupixent.
En ny fortolkning af taxiloven er i strid med EU-retten, Leo Pharma går efter milliardsalg af nyt middel, minister åbner for flyafgift og et ejendomsfirma, der gav alle medarbejdere bonus på 335.000 kr. i julegave.
Mikkel Aabenhus Hemmingsen taler med Kevin Grønnemann og Elizabeth Mønsted Johansen om de vigtigste nyheder fra life science-industrien i uge 44.
I'm joined by John Tomasello, Vice President & Head, Human Resources and Communications at Leo Pharma shares the importance of understanding the business and the impact it can have on your bottom line.Visit: www.hrdleaders.com/podcast to access the video recording and resources mentioned.Subscribe to our newsletter for the latest content on the future of HR: www.hrdleaders.com/subscribe
Redaktør Mikkel Aabenhus Hemmingsen taler med Kevin Grønnemann og Elizabeth Mønsted Johansen om de vigtigste nyheder fra life science-området i uge 23.
(00:35) Konsulenter for millioner og flybilletter på businessclass over Atlanten. Pengene har siddet løst i regeringens Disruptionråd, hvor alle de gamle kendinge fra fagbevægelsen, arbejdsgiverorganisationerne og erhvervslivet har siddet med. Men de politiske resultater? Indtil videre ingenting. (10:25) Danmark tredjestørste medicinselskab, Leo Pharma, er svømmet dybt ud på det åbne hav med milliarddyre investeringer og nye komplekse produkter. Indtil videre har man lavet et resultatmæssigt hul i jorden. Er det troværdigt, når topchef Gitte Aabo forsikrer, at alt går efter planen? Og er hun reelt den rette til at lede den skrantede virksomhed videre?(20:15) Navnet er Birgitte Bonnesen. Indtil for få måneder siden florerede der rygter om, at den magtfulde 62-årige finansboss var på blokken som ny topchef i Danske Bank. Nu lugter det mere af fyreseddel. Bonnesen sidder i spidsen for den svenske storbank, Swedbank, der i disse dage fedtes dybere og dybere ind i en hvidvaskskandale, der minder meget om Danske Banks.I studiet: Kommentator Anders Heide Mortensen, virksomhedsredaktør Søren Linding og debatredaktør Magnus Barsøe.
Medvirkende: Mikkel Svoldgaard Gadsboell, Vice President og Corporate Legal hos LEO Pharma. I denne særudgave af Magtens Tredeling besøger vi de jurister, der arbejder på den anden side af bordet - nemlig juristerne i det danske erhvervsliv. I dette afsnit er vi taget et smut forbi medicinalindustrien og besøger LEO Pharma. Her fortæller Vice President og Corporate Legal Mikkel Svoldgaard Gadsboell om, hvordan det er at arbejde som jurist blandt piller og præparater.
Medvirkende: Mikkel Svoldgaard Gadsboell, Vice President og Corporate Legal hos LEO Pharma. I denne særudgave af Magtens Tredeling besøger vi de jurister, der arbejder på den anden side af bordet - nemlig juristerne i det danske erhvervsliv. I dette afsnit er vi taget et smut forbi medicinalindustrien og besøger LEO Pharma. Her fortæller Vice President og Corporate Legal Mikkel Svoldgaard Gadsboell om, hvordan det er at arbejde som jurist blandt piller og præparater.
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: IQVIA, Novartis, AIFA, Roche, Boston Scientific, LEO Pharma, PellePharm, PPD, Phidea Group.Persone: Sergio Liberatore (IQVIA), Valerio De Molli (The European House), Pasquale Frega (Novartis), Francesco Ripa di Meana (Fiaso).Nuove terapie: patidegib.Patologie: fibrillazione atriale, anemia, beta-talassemia, sindrome di Gorlin, carcinoma basocellulare.Lavoro: Senior Medical Writer - Drug Safety, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: IQVIA, Novartis, AIFA, Roche, Boston Scientific, LEO Pharma, PellePharm, PPD, Phidea Group.Persone: Sergio Liberatore (IQVIA), Valerio De Molli (The European House), Pasquale Frega (Novartis), Francesco Ripa di Meana (Fiaso).Nuove terapie: patidegib.Patologie: fibrillazione atriale, anemia, beta-talassemia, sindrome di Gorlin, carcinoma basocellulare.Lavoro: Senior Medical Writer - Drug Safety, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Monsanto, Bayer, Leo Pharma, GSK, 23andMe.Persone: Rolf Ackermann (Monsanto), Heiko Schipper (Bayer), Arianna Bellucci (Università di Brescia).Nuove terapie: Alectinib, Dinutuximab Beta.Patologie: Tumore al polmone non a piccole cellule, Neuroblastoma, Diabete di tipo 1, Morbo di Parkinson, Cardiopatia Ischemica, Corea di Huntington.Lavoro: Global Pharmacovigilance Specialist, Medical Science Liaison, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Monsanto, Bayer, Leo Pharma, GSK, 23andMe.Persone: Rolf Ackermann (Monsanto), Heiko Schipper (Bayer), Arianna Bellucci (Università di Brescia).Nuove terapie: Alectinib, Dinutuximab Beta.Patologie: Tumore al polmone non a piccole cellule, Neuroblastoma, Diabete di tipo 1, Morbo di Parkinson, Cardiopatia Ischemica, Corea di Huntington.Lavoro: Global Pharmacovigilance Specialist, Medical Science Liaison, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
Globalist futurist speaker, author, consultant. Challenging the notion of leadership in the future. http://fastfuturepublishing.com Global futurist public speaker - Have delivered over 30 keynotes, presentations, or workshops in 8 countries. - Speaking topics include: preparing for a very different future, disruptive technologies, an emerging world of disruption and technology, the changing nature of work, collaborative futures. Futurist author - Book editor / co-editor: The Future of Business, Technology vs Humanity Unleashing Human Potential - The Future of AI in Business - Contributing author: Beyond Genuine Stupidity – Ensuring AI Serves Humanity The Future Reinvented: Reimagining Life, Society, and Business - Forthcoming books: Unleashing Human Potential - The Future of AI in Business 50 - 50 - Scenarios for the next 50 Years - Author /co-author of hundreds of articles published worldwide on the topics of: the future of AI, AI and employment, futurist predictions, future of business, smart cities, robotics, the future of the workforce. Consulting: - Worked with organisations to achieve their goals through creating real-time strategies, effective collaboration and sustainable change. - Clients included: The American Association for the Advancement of Science, Astra Zeneca, Baxter Healthcare, EU Directorate General for Communications Networks Content and Technology, Harman International Industries, International Legal Technology Association, Leo Pharma, National Health Service (UK), Pfizer, Premier Media Group, Terrapin Global Events, and UK Government Department of Business Innovation & Skills.
David Glanz talks to 2018 Clunies Ross Innovation Awardee, Dr Jim Aylward. Dr Aylward is the inventor of Picato, a novel anti-skin cancer drug developed from a folklore remedy that has been used to treat more than one million patients. Picato is a prescription drug with worldwide sales and major competitive advantages, and has become part of the arsenal for dermatology clinics. Dr Aylward discovered the drug after observing how sap from a weed successfully treated sunspots and isolating the active ingredients: an ingenane diterpene family of molecules, including ingenol mebutate. The drug requires only two to three days of treatment and no disfiguring surgery, protracted therapy or damage to DNA. The ex-CSIRO research scientist and entrepreneur co-founded Peplin Pty Ltd in 1998 to commercialise his invention, which was later sold to Leo Pharma A/S for around $306 million in 2009. Leo Pharma has set up an Australian office, employing more than 100 Australians and expanding the number of Australians skilled in pharmaceutical manufacture and clinical trial management. Dr Aylward’s support for translational research and development is ongoing. He established Oncolin to mentor start-up companies and served on the Advisory Panel for the University of Queensland’s iLab Incubator from 2006-2011. He also serves as a non-executive director of Wesley Medical Research. For his work, Dr Aylward was a state finalist in the Senior Australian of the Year awards and a joint winner of the 2012 Life Sciences Queensland Award. Now, he supports innovative companies through the State Government Mentoring for Growth initiative, and in 2012 he was awarded a certificate in appreciation of his commitment and support for growing Queensland businesses. He is also a member of a number of commercialisation committees at University of Queensland institutes, providing advice and support to encourage a new generation of entrepreneurs.
Today in FirstWord:
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Farmindustria, Grünenthal, AstraZeneca, Eli Lilly, LEO Pharma, Almirall, Bayer.Persone: Giorgio Bruno (Farmindustria), Massimo Scaccabarozzi (Farmindustria), Eduardo Sanchiz (Almirall), Gitte Aabo (LEO Pharma), Mario Salmona (Istituto Mario Negri), Axel Grothey (Mayo Clinic Rochester), Simona Gatti (Bayer), Giuseppe Testa (Istituto Europeo di Oncologia).Nuove terapie: nanovettori, cariprazina, octocog alfa protein free.Patologie: emicrania acuta, cefalea a grappolo, malattie dermatologiche, tumore del colon, schizofrenia, emofilia A, malattia del neurosviluppo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Farmindustria, Grünenthal, AstraZeneca, Eli Lilly, LEO Pharma, Almirall, Bayer.Persone: Giorgio Bruno (Farmindustria), Massimo Scaccabarozzi (Farmindustria), Eduardo Sanchiz (Almirall), Gitte Aabo (LEO Pharma), Mario Salmona (Istituto Mario Negri), Axel Grothey (Mayo Clinic Rochester), Simona Gatti (Bayer), Giuseppe Testa (Istituto Europeo di Oncologia).Nuove terapie: nanovettori, cariprazina, octocog alfa protein free.Patologie: emicrania acuta, cefalea a grappolo, malattie dermatologiche, tumore del colon, schizofrenia, emofilia A, malattia del neurosviluppo.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
Today in FirstWord:
Today in FirstWord:
Today in FirstWord:
This podcast is on LEO Pharma Inc. Dermatology Portfolio Review, A Product Theater with Parul Mody, PAwithC and was recorded at the 2013 SDPA Fall Conference in Atlanta.
-CHERATOSI ATTINICA: PRONTA GUARIGIONE CON IL GEL Un ciclo di terapia di due o tre giorni con un’unica somministrazione topica quotidiana, per trattare rapidamente le lesioni da cheratosi attinica, malattia della cute di cui soffrono milioni di persone in Italia e nel mondo soprattutto dopo i 40 anni. Arriva in Italia il gel a base di ingenolo mebutato, frutto dell’impegno di LEO Pharma, contro questa «forma di carcinoma allo stadio iniziale o “in situ”; le lesioni attiniche sono molto antiestetiche e ciascuna potenzialmente pericolosa perché a rischio di evoluzione maligna», afferma prof. Giampiero Girolomoni, Direttore della Clinica Dermatologica dell’Università degli Studi di Verona. La cheratosi attinica è ancora poco conosciuta e sotto-diagnosticata nonostante le lesioni possano progredire nel più frequente tumore della pelle non-melanoma, ovvero il carcinoma squamocellulare invasivo (SCC). Il farmaco è rimborsato dal Sistema Sanitario Nazionale. -ORTICARIA, OK DALL’EUROPA PER OMALIZUMAB La Commissione Europea ha approvato l’utilizzo di omalizumab come terapia aggiuntiva per il trattamento dell’orticaria cronica spontanea nei pazienti adulti e adolescenti con risposta inadeguata al trattamento con antistaminici H1. La dose approvata è di 300 mg per iniezione sottocutanea ogni 4 settimane. «Il trattamento con questo anticorpo monoclonale è efficace per il controllo dei sintomi in quei pazienti che non rispondono alla terapia tradizionale con antistaminici. E’ un grande passo avanti nella cura», afferma il Prof. Paolo Pigatto, Presidente SIDAPA (Società Italiana Dermatologia Allergologica Professionale e Ambientale) in occasione del Convegno ‘Skin to live in’ di Barcellona. Si stima che la prevalenza dell’orticaria cronica nella popolazione mondiale raggiunga l’1%, e fino a due terzi di questi pazienti soffrano della forma spontanea, patologia cutanea grave e logorante, caratterizzata dalla presenza sulla pelle di lesioni o pomfi rossi, gonfi, pruriginosi e talvolta dolorosi, che insorgono e ricorrono spontaneamente per oltre 6 settimane. -“OCCHIO AL DIABETE”, CAMPAGNA CONTRO LE COMPLICANZE OCULARI Prendere coscienza dei possibili rischi che il diabete può generare alla vista. E' l'obiettivo di 'Occhio al Diabete', la campagna promossa da Diabete Italia, dedicata a informare la popolazione sulle complicanze oculari, in particolare sulla retinopatia e l'edema maculare. Il tutto si articola in diverse iniziative, tra cui il sito www.occhioaldiabete.it , e il libretto 'Detto da Noi', con le linee guida per la prevenzione e la diagnosi precoce. Sono inoltre previste locandine e materiale informativo per i centri di diabetologia. «In un paese come l’Italia, dove esistono diverse realtà sanitarie e assistenziali, una campagna informativa come la nostra diventa indispensabile per rendere il paziente più esperto e sensibile anche alle complicanze cui possono essere soggetti organi importanti come gli occhi», afferma Salvatore Caputo, Presidente di Diabete Italia. Due sono i fattori di rischio che influiscono maggiormente sulla manifestazione della patologia: il tempo trascorso dall’insorgenza del diabete (quanto più a lungo si soffre di diabete, tanto più alta è la probabilità di soffrire di complicanze retiniche) e lo scarso controllo della glicemia e della pressione. Gli specialisti consigliano il controllo della retina ogni due anni, mentre in presenza di retinopatia deve essere continuativo ed eseguito a cadenza almeno annuale; quindi l'Esame del fondo oculare, fluorangiografia e OCT. -ARRIVA ‘LA PILLOLA DELL’AMORE SENZA ATTESA’ Un'efficacia prolungata, che si mantiene per oltre 6 ore dall'assunzione e che inizia ad agire entro 15 minuti; riduzione della possibilità di comparsa di effetti collaterali e una minor probabilità di interazioni con medicinali e cibi; dosaggi che non vanno “aggiustati” in caso di pazienti anziani, con diabete o con insufficienza renale. Tante caratteristiche per rendere la vita di coppia del tutto naturale. E’ quanto permette ‘Avanafil’, “la pillola dell’amore senza attesa”, presentata al congresso di urologia di Stoccolma. «Il 40-50% dei pazienti con disfunzione erettile non ottiene una vita sessuale pienamente soddisfacente e abbandona presto la terapia– spiega Vincenzo Mirone, Segretario Generale della Società Italiana di Urologia (SIU) – Questo accade perché le aspettative dei pazienti nei confronti del trattamento farmacologico sono molteplici e non sempre le attuali pillole riescono a rispondere a tutti i bisogni. Molti pazienti cercano soluzioni più rapide, per vivere con più naturalezza il rapporto».
-IPOTIROIDISMO: DIFFICILE SEGUIRE LA PRESCRIZIONE MEDICA Il 37% delle persone che soffre di ipotiroidismo dichiara di sentirsi “diverso” da quando ha questo problema e il 31% è preoccupato per la “dipendenza a vita” da un farmaco. Tuttavia ben 2 pazienti su 3 ammettono di non rispettare le indicazioni di cura del proprio medico; cattiva abitudine che trova riscontro nelle dichiarazioni degli stessi medici, secondo i quali 1 paziente su 2 (il 48%) ha scarsa adesione alla terapia con levotiroxina. - ESISTE LA TERAPIA SE IL RAPPORTO SI CONSUMA PRESTO Parlare di problemi sessuali è sempre complicato e fonte di imbarazzo ed ansia, soprattutto per gli uomini. L'Eiaculazione Precoce è forse una condizione ancora più difficile, perché non sempre è riconosciuta come un problema medico "reale", con cause proprie e possibili trattamenti. Il disturbo si configura nella sfera del tempo (si raggiunge in ‘picco’ in meno di un minuto o poco più), nella mancanza di controllo e nell’angoscia e frustrazione, che si riverbera poi nel rapporto di coppia. Se un uomo non sa che l'Eiaculazione Precoce è un problema medico, probabilmente non chiederà l'aiuto di uno specialista. Questo è esattamente ciò che vuol cambiare la campagna internazionale ‘Not just a moment’, presentata oggi a Madrid, facendo arrivare i suoi messaggi semplici ma cruciali verso il maggior numero possibile di uomini. -HAI LA PSORIASI? NON NASCONDERTI Due milioni e mezzo di persone devono far i conti con la psoriasi lieve-moderata, malattia della pelle con impatto evidente sulla qualità di vita. Non è una malattia contagiosa eppure compromette le gli affetti, le relazioni e porta con sé tanti pregiudizi. Per superare questi ostacoli nasce lo spot ‘Hai la psoriasi? Non nasconderti!’, promosso nell’ambito della Campagna nazionale ‘Che ne sai di psoriasi? Conoscerla per curarla’ promossa dall’Associazione per la Difesa degli Psoriasici (A.DI.PSO.). Lo spot è realizzato con il patrocinio dell’Associazione Dermatologi Ospedalieri Italiani (ADOI) e della Società italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse (SIDeMaST), con il contributo incondizionato di LEO Pharma. -TERAPIA DI COMBINAZIONE CONTRO IL MELANOMA La combinazione tra ipilimumab, innovativo anticorpo monoclonale, disponibile in Italia da pochi giorni, con la chemioterapia tradizionale a base di fotemustina, riduce il melanoma in misura significativa nel 46,5% dei pazienti e ha mostrato risultati incoraggianti anche in caso di metastasi cerebrali. Lo afferma lo studio ‘Nibit M1’, frutto della ricerca del Network Italiano per la Bioterapia dei Tumori, pubblicato sulla prestigiosa rivista scientifica “Lancet Oncology”. Il prossimo passo contro questo tipo di tumore della pelle è il ‘Nibit M2’.
-AL VIA CAMPAGNA NAZIONALE PSORIASI LIEVE MODERATA "Che ne sai di Psoriasi? Conoscerla per curarla" è la Campagna nazionale promossa da A.DI.PSO., l'Associazione per la Difesa degli Psoriasici, con il supporto di LEO Pharma, per sensibilizzare gli italiani sulla psoriasi lieve-moderata, una malattia della pelle spesso non riconosciuta e non adeguatamente trattata che colpisce soggetti predisposti geneticamente. Oltre il 50% dei pazienti non si cura in modo costante e si rivolge al dermatologo solo quando i sintomi diventano troppo fastidiosi. -- UNA CARTA DEI SERVIZI SANITARI PER I DETENUTI Garantire, a tutti i detenuti, l'erogazione delle prestazioni di prevenzione, diagnosi e cura sulla base degli obiettivi generali di salute, dei progetti specifici e dei livelli essenziali di assistenza garantiti dalla Regione. Sono questi gli obiettivi della Carta dei servizi sanitari per i detenuti delle due carceri di Civitavecchia, approvata dalla Asl Rm F. Il documento, primo del genere nel Lazio ed uno dei pochi già in vigore in Italia, è stato presentato l'altro giorno. -SCLEROSI MULTIPLA: MENO RECIDIVE E PROGRESSIONE DISABILITA' CON BG-12 (DIMETIL FUMARATO) PER VIA ORALE Al Congresso del Comitato Europeo per il Trattamento e la Ricerca sulla Sclerosi Multipla (ECTRIMS) di Lione, in Francia, sono stati annunciati i nuovi dati provenienti dagli studi di valutazione del BG-12 (dimetil fumarato) per via orale, che forniscono ulteriori evidenze sugli importanti effetti clinici e radiologici del farmaco in pazienti affetti da sclerosi multipla recidivante remittente (SMRR) e ne confermano ulteriormente il buon profilo di sicurezza. - IL FARMACISTA DI REPARTO È ARMA ANTI-SPRECHI. Con l'introduzione del farmacista di dipartimento in tutti i reparti di oncologia italiani (oltre 300) sarebbe possibile risparmiare fino al 40% delle risorse ogni anno. La cifra si ricava dai risultati di un progetto pilota, avviato nel marzo 2010 e terminato nel giugno 2011, condotto dalla SIFO (Società Italiana di Farmacia Ospedaliera e dei Servizi Farmaceutici delle Aziende Sanitarie) in collaborazione con il Ministero della Salute in 5 ospedali (Torino, Padova, Ancona, Bari, Taormina).
© 2020-2025 Ivy Podcast Discovery LLC
